Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HULK: Suprachoroidal CLS-TA in Diabetic Macular Edema
NCT02949024Phase 2Completed
- Sponsor
- Clearside Biomedical
- Start
- Nov 2016
- Primary completion
- Oct 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of triamcinolone in diabetic macular edema (DME) (2 arms), sponsored by Clearside Biomedical. Primary endpoint: Treatment Emergent Adverse Events and Serious Adverse Events at 6 months. Started Nov 2016; status: completed.
02
Drugs
triamcinolone
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02949024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949024.